PE20080534A1 - Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr - Google Patents
Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdrInfo
- Publication number
- PE20080534A1 PE20080534A1 PE2007000458A PE2007000458A PE20080534A1 PE 20080534 A1 PE20080534 A1 PE 20080534A1 PE 2007000458 A PE2007000458 A PE 2007000458A PE 2007000458 A PE2007000458 A PE 2007000458A PE 20080534 A1 PE20080534 A1 PE 20080534A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridines
- nr3cor6
- remains
- refers
- kdr inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical group NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 150000004892 pyridazines Chemical group 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 abstract 1
- 229940122858 Elastase inhibitor Drugs 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 102000016387 Pancreatic elastase Human genes 0.000 abstract 1
- 108010067372 Pancreatic elastase Proteins 0.000 abstract 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003602 elastase inhibitor Substances 0.000 abstract 1
- PONAXVAFSSUYFZ-UHFFFAOYSA-N furo[2,3-d]pyridazine Chemical compound N1=NC=C2OC=CC2=C1 PONAXVAFSSUYFZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DE PIRIDINA Y PIRAZINA SUSTITUIDOS DE FORMULA (I), DONDE R1 Y R2 FORMAN UN PUENTE CON DOS RESTOS T2 Y UN RESTO T3, FORMANDO CON EL ANILO UN BICICLICO, EN DONDE T2 ES N, CH, 0 CG1 Y T3 ES S, O, CR4G1, C(R4)2 O NR3; X ES O, S, Y NR3; Y ES ALQUILENO INFERIOR, CH2-O-, CH-NH-, ENTRE OTROS; q ES DE 0 A 3; G3 ES UN RESTOS MONO O BIVALENTE SELECCIONADO DE ALQUILO INFERIOR, NR3COR6, OR6, ENTRE OTROS; A, B, D, E, L SON INDEPENDIENTEMENTE N O CH, CON LA CONDICION: a) EL NUMERO TOTAL DE ATOMOS DE N EN EL ANILLO QUE LOS CONTIENE SEA DE 0 A 3; b) CUANDO L ES CH, Y UN G3 ES UN SUSTITUYENTE MONOVALENTE AL MENOS UNO DE A Y D ES N; J ES ARILO, PIRIDILO O CICLOALQUILO; q' ES DE 0 A 5; G4 E UN RESTO MONO O BIVALENTE DE -N(R6)2; NR3COR6; HALOGENO, ALQUILO, ETC; Z ES N O CR4. SON SELECCIONADOS: 4-(4-CLOROFENILAMINO)-7-(2-METILAMINOCARBONIL-4-PIRIDILMETOXI)FURO-[2,3-d]PIRIDAZINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA OPCIONALMENTE COMBINADA CON AL MENOS UN INHIBIDOR DE ELASTASA O DE QUINASA TAL COMO GLIVEC. ESTOS COMPUESTOS SON INHIBIDORES DE KDR Y SON UTILES EN EL TRATAMIENTO DE DOLENCIAS MEDIADAS POR VEGF TAL COMO HIPERTENSION PULMONAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007929 | 2006-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080534A1 true PE20080534A1 (es) | 2008-07-13 |
Family
ID=38190754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000458A PE20080534A1 (es) | 2006-04-15 | 2007-04-13 | Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8304406B2 (es) |
| EP (1) | EP2010173A1 (es) |
| JP (1) | JP2009533479A (es) |
| AR (1) | AR060431A1 (es) |
| CA (1) | CA2648957A1 (es) |
| DO (1) | DOP2007000073A (es) |
| PE (1) | PE20080534A1 (es) |
| TW (1) | TW200808317A (es) |
| UY (1) | UY30281A1 (es) |
| WO (1) | WO2007118602A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3323821A1 (en) | 2012-11-08 | 2018-05-23 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN105294686B (zh) * | 2015-11-30 | 2017-03-22 | 郑州大明药物科技有限公司 | 一种利奥西呱的制备方法 |
| WO2018080216A1 (en) * | 2016-10-28 | 2018-05-03 | Daewoong Pharmaceutical Co., Ltd. | Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same |
| CN107129502B (zh) * | 2017-04-13 | 2022-08-05 | 泰州亿腾景昂药业股份有限公司 | EOC315 Mod.I晶型化合物及其制备方法 |
| CN109232546B (zh) * | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| EP4087561A4 (en) * | 2020-01-07 | 2024-02-14 | Shanghai Huayu Biotechnology Co., Ltd. | CANCER COMBINATION THERAPY USING A CHK INHIBITOR |
| US20240294537A1 (en) | 2021-07-07 | 2024-09-05 | Teva Pharmaceuticals International Gmbh | SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1107964B8 (en) * | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| AR025752A1 (es) * | 1999-09-28 | 2002-12-11 | Bayer Corp | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
| US20020173464A1 (en) * | 2000-12-01 | 2002-11-21 | King George L. | Modulation of pericyte proliferation |
| WO2003059354A2 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| DE10310908A1 (de) * | 2003-03-13 | 2004-09-23 | Bayer Healthcare Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von pulmonaler Hypertonie |
| EP1740203A4 (en) * | 2004-03-31 | 2008-02-13 | Eyegene Inc | POLYPEPTIDE INDUCING THE ANGIOPOIETINE SECRETION |
| CN101031293A (zh) * | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
| EP1746099A1 (en) * | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| WO2007039736A1 (en) | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
-
2007
- 2007-04-03 US US12/297,217 patent/US8304406B2/en not_active Expired - Fee Related
- 2007-04-03 EP EP07723926A patent/EP2010173A1/en not_active Withdrawn
- 2007-04-03 WO PCT/EP2007/002985 patent/WO2007118602A1/en not_active Ceased
- 2007-04-03 CA CA002648957A patent/CA2648957A1/en not_active Abandoned
- 2007-04-03 JP JP2009505742A patent/JP2009533479A/ja active Pending
- 2007-04-12 AR ARP070101559A patent/AR060431A1/es not_active Application Discontinuation
- 2007-04-12 UY UY30281A patent/UY30281A1/es not_active Application Discontinuation
- 2007-04-13 PE PE2007000458A patent/PE20080534A1/es not_active Application Discontinuation
- 2007-04-13 TW TW096112951A patent/TW200808317A/zh unknown
- 2007-04-13 DO DO2007000073A patent/DOP2007000073A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009533479A (ja) | 2009-09-17 |
| DOP2007000073A (es) | 2007-11-15 |
| TW200808317A (en) | 2008-02-16 |
| WO2007118602A1 (en) | 2007-10-25 |
| US20100113452A1 (en) | 2010-05-06 |
| AR060431A1 (es) | 2008-06-18 |
| CA2648957A1 (en) | 2007-10-25 |
| EP2010173A1 (en) | 2009-01-07 |
| US8304406B2 (en) | 2012-11-06 |
| UY30281A1 (es) | 2007-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080534A1 (es) | Compuestos derivados de piridinas y piridazinas sustituidos como inhibidores de kdr | |
| JP2012528166A5 (es) | ||
| RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| JP2008538750A5 (es) | ||
| EA200800478A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR052232A1 (es) | Derivados de 5-heteroariltiazoles | |
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| JP2009543867A5 (es) | ||
| NO20080392L (no) | Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1 | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| AR049497A1 (es) | Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacion | |
| EA200601125A1 (ru) | 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| PE20090733A1 (es) | Derivados de pirazina como bloqueadores de los canales de sodio epitelial | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| EA201390022A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
| JP2012511588A5 (es) | ||
| AR069740A1 (es) | Compuestos nucleosidos antivirales | |
| PE20020219A1 (es) | Derivados de 6-fenilpirrolpirimidindiona como inhibidores de fosfodiesterasa 5 | |
| AR087355A1 (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |